Abiopharma

🔍 Congleton Jon (Director)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Sold 9,119 shares of Common Stock at $32.2083 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 646,268.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 7,117 shares of Common Stock at $33.1505 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 639,151.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.8400 to $32.8028. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.8439 to $33.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.